Theriva Biologics Reports $4.4 Million Net Loss, Focuses on Oncology Pipeline

Theriva Biologics, Inc. reported a net loss of $4.4 million, or $0.45 per share, for the three months ended September 30, 2025, a significant decrease from the $7.7 million loss, or $6.81 per share, recorded in the same period last year. For the nine months ending September 30, 2025, the company reported a net loss of approximately $21.7 million, compared to $21.2 million for the same period in 2024. The decrease in quarterly losses is attributed to reduced general and administrative expenses, which fell to $1.9 million from $2.3 million, and a slight decline in research and development expenses, which decreased to $2.6 million from $2.7 million.

The company’s total assets decreased to $30.8 million as of September 30, 2025, down from $35.4 million at the end of 2024. Current assets also saw a decline, primarily due to a reduction in cash and cash equivalents, which fell to $7.5 million from $11.6 million. Current liabilities increased significantly to $11 million from $7.6 million, driven by a rise in accrued expenses, which jumped to $7.7 million from $3.4 million. The increase in liabilities reflects the company's ongoing financial challenges and the need for additional capital to support its operations.

Strategically, Theriva Biologics is focusing on its oncology pipeline, particularly the development of its lead product candidate, VCN-01, an oncolytic adenovirus currently in clinical trials for metastatic pancreatic ductal adenocarcinoma (mPDAC) and retinoblastoma. The company has recently implemented a workforce reduction of approximately 32% to streamline operations and direct resources towards business development and clinical trial preparations. This restructuring is expected to save approximately $1.8 million annually in compensation and benefits.

In terms of financing, Theriva Biologics has been actively pursuing additional capital through various means, including an at-the-market (ATM) offering and warrant exercises. As of early November 2025, the company reported cash and cash equivalents of approximately $15.5 million, which it believes will be sufficient to fund operations into the first quarter of 2027. However, the company continues to face uncertainties regarding its ability to raise additional funds necessary for future clinical trials and operational needs, raising concerns about its long-term viability.

Looking ahead, Theriva Biologics plans to focus on advancing its clinical programs, particularly VCN-01, while exploring strategic partnerships and financing opportunities to support its development efforts. The company is also preparing for upcoming meetings with regulatory agencies regarding its clinical trials, which will be critical for its future growth and success in the competitive biopharmaceutical landscape.